American Society of Hematology

What can proteomics reveal about new treatment strategies for NPM1-mutant Acute Myeloid Leukemia (AML)?

Join the next ASH Journal Club webinar to:

Explore how integrated omics data is advancing our understanding of NPM1-mutant AML.

Learn how mouse models and CRISPR screening are uncovering new therapeutic vulnerabilities.

Hear from experts on how these discoveries could shape future treatment strategies.

Enroll today: https://ow.ly/IVTm50ZoRTt

Blood Journals Portfolio

Registration is now open for the ASH Foundation Run/Walk! 👟

Start your Sunday at with a 3K or 5K through New Orleans or participate virtually from anywhere in the world.

Proceeds from every registration support the , funding additional ASH awards to sustain and advance vital hematologic research.

Register today: https://ow.ly/USEo50ZnWa9

The ASH Committee on Communications just wrapped up a productive Summer 2026 meeting! Members discussed the continued work of , including advocacy for hematology research, access to care, and trusted information for patients and the broader community. Thank you to all committee members for their dedication to advancing the field.

The preliminary program for the world's premier event in classical and malignant hematology is now available!

Learn about the topics, speakers, and more you can expect to discover during the 68th ASH Annual Meeting and Exposition: https://ow.ly/n73Z50ZmSEC

📅 Member registration and housing open July 22 at 11 a.m. ET

ASH continues to engage with the Centers for Medicare & Medicaid Services (CMS) on policies that impact patient access to care. In comments on the proposed rule addressing interoperability and prior authorization for drugs, ASH expressed support for efforts to modernize and streamline electronic prior authorization, increase transparency, and reduce administrative burden on patients and providers. The Society also emphasized the importance of standardized prior authorization requirements across health plans, appropriate clinical oversight of artificial intelligence (AI) and automated decision-making tools, and safeguards to help ensure timely access to medically necessary therapies.

Read the letter: https://ow.ly/o1lQ50ZmJ99

The Trump Administration has proposed a new rule that applies to all federal agencies and would dramatically reshape the federal grant-making process and undermine research integrity. By converting the Uniform Guidance for Federal Financial Assistance into rigid regulation, the proposal would inject red tape, politicize funding decisions, and limit scientific dissemination across federal agencies.

ASH is gravely concerned that this rule will weaken NIH-funded hematology advances, delay cures and clinical trials, and jeopardize patient health outcomes. It would increase administrative burden, discourage early-career researchers, and threaten rare disease studies by curbing international collaboration.

ASH urges the Administration to rescind this proposal immediately to protect patients, preserve scientific integrity, and safeguard the nation’s medical research enterprise.

Read the full statement: https://ow.ly/BK5t50ZmoRH

There’s still time to submit your abstract for .

Present your research on hematology’s biggest stage at the 68th ASH Annual Meeting and Exposition. From early discoveries to practice-changing data, ASH is where the latest advances in the field take center stage.

📅 Submit by August 4, 2026 at 11:59 p.m. Pacific time
🔗 https://ow.ly/kc2850Zeb32